Right Turn Show - Optimal Use of Dapagliflozin and its Combinations in Specialty Care Settings MD Brand Connect30 Oct 2024 10:00 AM ISTBringing you the 'Right Turn Show,' where we focus on the optimal use of dapagliflozin and its combinations in speciality care settings. In this...
Exemed Pharmaceutical Gets CDSCO Panel Nod To Manufacture, Market Empagliflozin plus Sitagliptin FDC Dr. Divya Colin28 Aug 2024 6:15 PM ISTNew Delhi: Exemed Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Sitagliptin with basal-plus insulin regimen more effective than insulin therapy alone for type 2 diabetes: Study Medha Baranwal16 April 2024 9:45 AM ISTMexico: SITA-PLUS hospital trial published in the Journal of Diabetes and its Complications has shed light on the safety and efficacy of sitagliptin...
Synokem Pharma Gets CDSCO Panel Nod To Study Antidiabetic FDC Dr. Divya Colin27 Feb 2024 6:00 PM ISTNew Delhi: The drug major Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
NPPA fixes retail prices of 39 formulations Roshni Dhar8 Feb 2024 5:42 PM ISTThe National Pharmaceutical Pricing Authority (NPPA) has announced that it has fixed retail prices of 39 formulations under the Drugs (Prices Control)...
Health Bulletin 08/February/2024 Roshni Dhar8 Feb 2024 4:53 PM ISTHere are the top health news for the day:NMC requires video recording of annual MBBS exams for renewal permissionsThe National Medical Commission...
NPPA fixes price for various FDCs having Sitagliptin, Linagliptin Ruchika Sharma7 Feb 2024 6:00 PM ISTNew Delhi: The National Pharmaceutical Pricing Authority (NPPA) has announced that it has fixed retail prices of 39 formulations under the Drugs...
Torrent Pharma Gets CDSCO Panel Nod To study antidiabetic FDC Empagliflozin plus Sitagliptin Dr. Divya Colin17 Jan 2024 6:00 PM ISTNew Delhi: The drug major Torrent Pharmaceutical has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Modify eGFR value as per standard guidelines: CDSCO Panel Tells Hetero Lab on Antidiabetic FDC Drug Dr. Divya Colin31 Dec 2023 5:15 PM ISTNew Delhi: Reviewing the drug major Hetero Lab's revised Phase III clinical trial protocol of fixed-dose combination antidiabetic drug Sitagliptin...
Conduct Phase III CT: CDSCO Panel Tells Akum Pharmaceutical on Antidiabetic FDC Dr. Divya Colin10 Dec 2023 6:00 PM ISTNew Delhi: Rejecting the proposal for the clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
First Indian Evidence: Triple FDC (DAPA, SITA, MET ER) Yields Better HbA1c Reduction in T2DM Patients Uncontrolled on Existing Therapy Dr. Kamal Kant Kohli2 Dec 2023 11:43 AM ISTAn approach of using a once-daily triple fixed-dose combination of dapagliflozin, sitagliptin, and metformin ER (extended-release) in Indian type 2...
Conduct Phase III clinical trial: CDSCO to Zydus Healthcare over FDC Empagliflozin plus Sitagliptin Dr. Divya Colin12 Nov 2023 4:00 PM ISTNew Delhi: In response to the proposal presented by the drug major Zydus Healthcare, the Subject Expert Committee ( SEC) functional under the Central...
